Oral and poster presentations on key VMX-001 data in San Diego from 7-10 December

Leiden, The Netherlands, 3 December 2024 – VarmX, a biotech company developing innovative approaches for the bypass of direct oral anticoagulants targeting activated factor Xa (FXa DOACs) and inherited coagulation disorders will be showcasing its latest pre-clinical and clinical data in oral and poster presentations on the effectiveness of lead asset, VMX-C001 at the 66th ASH Annual Meeting and Exposition in San Diego, from 7 – 10 December 2024. 

Dr Daniël Verhoef, Director of Research will be speaking on Paradigm Shifts in the Reversal of DOACs on 8 December at 4.30pm in San Diego Convention Center, Room 28 A-D, as part of the Scientific Program session on Paradigm Shifts in Hemostasis: From Mechanisms to Therapies and Back session. 

He will also be presenting a poster titled Vmx-C001 Prevents Rivaroxaban-Induced Bleeding in a Liver Injury Model in Cynomolgus Monkeys, on 7 December from 5.30pm-7.30pm in San Diego Convention Center, Halls G-H, as part of the Coagulation and Fibrinolysis: Basic and Translational session.

Dr Ged Short, CMO will be presenting a poster titled Phase 1 Study of the Safety and Pharmacodynamics of a Single Dose of Vmx-C001 in Healthy Subjects with and without FXa Direct Oral Anticoagulants on 8 December at 6:00pm – 8:00pm in San Diego Convention Center, Halls G-H  as part of the Thrombosis and Anticoagulation: Clinical and Epidemiological session.

VarmX’s founder and special adviser Prof. Pieter Reitsma will also be attending the conference.